TARS Live signaler | Maksimer profitt med Getagraph.com

SELG 116934 min ago

@ $29.83

Utstedt: 13 feb 2024 @ 17:42

Avkastning: 23.53%

Forrige signal: feb 9 - 15:30

Forrige signal: Kjøp

Avkastning: -3.38 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions...

Stats
Dagens volum	652 217
Gjennomsnittsvolum	697 548
Markedsverdi	1.38B
EPS	$0 ( 2024-02-27 )
Neste inntjeningsdato	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.98
ATR14	$0.0780 (0.21%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-15	Mottiwala Aziz	Buy	12 938	Common Stock
2024-03-18	Mottiwala Aziz	Sell	4 766	Common Stock
2024-03-15	Mottiwala Aziz	Sell	8 148	Restricted Stock Units
2024-03-15	Mottiwala Aziz	Sell	4 790	Restricted Stock Units
2024-03-15	Wahl Bryan	Buy	12 038	Common Stock

INSIDER POWER
31.24
Last 100 transactions
Buy: 1 038 524 \| Sell: 656 594

Volum Korrelasjon

Lang: 0.33 (neutral)

Kort: -0.65 (weak negative)

Signal:(63.364) Neutral

Tarsus Pharmaceuticals, Korrelasjon

10 Mest positive korrelasjoner
NVCN	0.951
AGNCP	0.949
SILK	0.943
VCEL	0.941
ADTH	0.94
TIOAU	0.936
ROVR	0.935
TIOA	0.935
BRIVU	0.931
INBK	0.93

10 Mest negative korrelasjoner
CRCT	-0.945
SGML	-0.943
VRM	-0.942
OSTK	-0.94
TBLT	-0.94
IRBT	-0.939
MYMD	-0.939
SNAX	-0.939
REVB	-0.936
TENX	-0.931

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Tarsus Pharmaceuticals, Korrelasjon - Valuta/Råvare

-0.79
( moderate negative )

-0.75
( moderate negative )

0.00
( neutral )

-0.74
( moderate negative )

-0.51
( weak negative )

0.19
( neutral )

Tarsus Pharmaceuticals, Økonomi

Annual	2023
Omsetning:	$17.45M
Bruttogevinst:	$15.85M (90.87 %)
EPS:	$-4.62

FY	2023
Omsetning:	$17.45M
Bruttogevinst:	$15.85M (90.87 %)
EPS:	$-4.62

FY	2022
Omsetning:	$25.82M
Bruttogevinst:	$24.86M (96.30 %)
EPS:	$-2.52

FY	2021
Omsetning:	$57.03M
Bruttogevinst:	$57.03M (100.00 %)
EPS:	$-0.00200

Financial Reports:

No articles found.

Tarsus Pharmaceuticals,

Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Sanntidsoppdatering for Tarsus Pharmaceuticals, [TARS]

Upcoming Earnings Alert